• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Foundation Medicine

< Previous 1 2 Next >
U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
October 11, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide Tumor Molecular Profiling to Veterans with Cancer
September 24, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme Platform
September 04, 2024
From Foundation Medicine
Via Business Wire
U.S. Food and Drug Administration Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
September 03, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform
August 28, 2024
From Foundation Medicine
Via Business Wire
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
July 01, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
June 12, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
May 29, 2024
From Foundation Medicine
Via Business Wire
Tickers PMVP
Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting
May 24, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S.
May 21, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 06, 2024
From Foundation Medicine
Via Business Wire
Foundation Medicine Appoints Dan Malarek as Chief Executive Officer
December 14, 2023
From Foundation Medicine
Via Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
November 20, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung Cancer
November 15, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations
October 26, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
October 21, 2023
From Foundation Medicine
Via Business Wire
New Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown Primary Origin (CUP)
October 20, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
October 19, 2023
From Foundation Medicine
Via Business Wire
FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Pfizer’s BRAFTOVI® (encorafenib) in Combination With MEKTOVI® (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC
October 12, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine and Natera Announce Broad Clinical Launch and Medicare Coverage of FoundationOne®Tracker
October 10, 2023
From Foundation Medicine
Via Business Wire
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
October 09, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces the Launch of FoundationOne®RNA Assay for Research and Investigational Use
September 06, 2023
From Foundation Medicine
Via Business Wire
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
August 14, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Awards Grant to Moffitt Cancer Center and LUNGevity to Help Remove Barriers to Information About Personalized Oncology for Black Patients
July 31, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Leadership Appointments
June 15, 2023
From Foundation Medicine
Via Business Wire
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer
June 09, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Collaboration with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Selected Marketed and Pipeline Treatments
June 05, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine Expands Monitoring Portfolio with Launch of FoundationOne®Monitor
June 02, 2023
From Foundation Medicine
Via Business Wire
FoundationOne®Liquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY® (mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer
May 04, 2023
From Foundation Medicine
Via Business Wire
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
April 11, 2023
From Foundation Medicine
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap